Hyderabad, 30 June: Ferring
Pharmaceuticals joined an elite list of European pharma majors to invest in a
facility in Genome Valley, Hyderabad, as they laid the foundation for their
state-of-the art R&D laboratory and manufacturing facility today. Their
ground-breaking ceremony was graced by the Honorable Minister for Industries, IT,
MA & UD Shri K Taraka Rama Rao and several dignitaries including senior
TSIIC officials. Ferring Pharmaceuticals is a Switzerland based Euro 2 billion
research-driven specialty biopharmaceutical group and is a leader in
reproductive medicine and women’s health with strong presence in specialty
areas within gastroenterology and urology. The group has headquarters in St.
Prex, Switzerland with a portfolio of manufacturing facilities across Europe,
North America, South America, China and India marketing its products in over
110 countries.
Ferring established its Indian
subsidiary in 1997 and has thus far established a manufacturing facility, an
R&D centre and commercial operations in Maharashtra. Ferring India CEO Mr
Suresh Pattathil mentioned that Ferring’s association with Hyderabad began
after the group’s chairman Dr. Fredrick Paulsen expressed a strong interest in
investing in the city on back of progressive governance and forward-looking
industry policies, and presence of the right infrastructure, skilled manpower
pool for R&D and manufacturing which are conducive to new business
investments. The new facility will also add to group’s global R&D
capabilities and will cater to building a pool of novel research for emerging
healthcare challenges around the world. Ferring plans to complete the project
in three phases with a total proposed investment of US$250 million, with an
estimated INR 235 Crores into the first phase itself.
Welcoming Ferring to Genome Valley, Hon Minister said “we are
delighted to have Ferring Pharma join the impressive list of companies who are
present in this cluster”. He also mentioned that the street could be named as
European Avenue, given the presence of almost all top European companies like
Novartis, GSK, Chemo, Lonza and now Ferring, among others.
Genome Valley has emerged as one of
the leading life sciences Clusters in Asia and Genome Valley 2.0 will attract a
range of global companies into the cluster helping the State consolidate its
position as the undisputed leader in the life Sciences sector. Valley is
expected to keep growing as it has started delivering cluster synergies which
are critical in current stage of life science industries. USP has initiated a
unique academic program to train lifescience professionals which would be helpful
in ensuring availability of trained manpower for the fast-growing cluster” he
stated
-Press club
No comments :
Write comments